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Stefan Fruehauf,1 Guido Tricot2Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are considered the standard of
care for many malignancies, including lymphoma, myeloma, and some leukemias. In many cases, mobilized
peripheral blood has become the preferred source of hematopoietic stem cells. The efficacy of different
mobilization regimens and transplantation outcomes based on cell doses has been well studied; however,
the characteristics of the stem cell graft may be of equal importance with respect to patient outcomes fol-
lowing autologous or allogeneic HSCT. This review summarizes available preclinical and clinical data for bone
marrow and mobilized peripheral blood HSCT characteristics, defined as the cell types found in the graft as
well as their gene expression profiles. It also explores how graft characteristics can affect bone marrow hom-
ing, engraftment, immune reconstitution, and other posttransplantation outcomes in both the allogeneic and
autologous HSCT settings.
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Hematopoietic stem cell transplantation (HSCT)
as a treatment modality for disease dates back to
studies performed in the late 1930s and early 1940s
[1-5]. An important breakthrough occurred in the
1970s with the detection of the human leukocyte
antigen (HLA) system, which allowed allogeneic
HSCT without potentially fatal complications, such
as rejection and severe graft-versus-host disease
(GVHD) [6,7]. A second important breakthrough
occurred in the mid-1980s, when several groups
showed that it was possible to collect hematopoietic
stem cells (HSCs) from the peripheral blood
by apheresis after administration of chemotherapy
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6/j.bbmt.2010.02.002colony-stimulating factor (G-CSF) (filgrastim [Neup-
ogen]; Amgen, Thousand Oaks, CA) and granulocyte-
macrophage colony-stimulating factor (GM-CSF)
(sargramostim [Leukine]; Genzyme, Cambridge, MA)
[12,13].
Peripheral blood remains the most common
source of HSCs, and several agents are available or un-
der investigation for HSC mobilization. Chemothera-
peutic agents, such as cyclophosphamide, and other
cytostatic drugs have been used in conjunction with
growth factors to mobilize stem cells into the periph-
eral blood [14-16]. In addition, disease-specific regi-
mens, including ICE (ifosfamide, carboplatin, and
etoposide), RICE (rituximab1 ICE), IVE (ifosfamide,
vincristine, and etoposide), DHAP (cisplatin, cytara-
bine, and dexamethasone), and D-PACE (dexametha-
sone, cisplatin, adriamycin, cyclophosphamide, and
etoposide), have been used in combination with cyto-
kines for HSC mobilization into the peripheral blood
[17-20]. Cytokines alone (eg, G-CSF, GM-CSF, and
stem cell factor [SCF; Stemgen; Biovitrum, Stock-
holm, Sweden]) have been studied extensively and
shown to effectively mobilize HSCs, but typically re-
sult in lower CD341 cell numbers [21]. Plerixafor
(Mozobil; Genzyme), a new small molecule, has been
approved by the US Food and Drug Administration
and European Medicines Agency for use in HSC mo-
bilization for autologous HSCT (aHSCT) in patients
with lymphoma and multiple myeloma (MM).1629
1630 Biol Blood Marrow Transplant 16:1629-1648, 2010S. Fruehauf and G. TricotAgents currently under investigation for use in
HSC mobilization but not currently approved by reg-
ulatory authorities include Cdc42 activity-specific
inhibitor and natalizumab [22-24]. Cdc42 activity-
specific inhibitor is a small molecule that inhibits the
activity of Cdc42, a Rho GTPase shown to facilitate
the interactions of HSCs with the bone marrow
microenvironment [25]. Natalizumab is an a-very
late antigen (VLA)-4/CD49d monoclonal antibody
against b1 integrin that interferes with VLA-4 (a4,
b1) interactions with the bone marrow [22,23].
Small-molecule inhibitors of VLA-4 are currently be-
ing studied in experimental settings in combination
with plerixafor, and the finding of their synergistic
effect on mobilization warrants further exploration of
their clinical use [26].
This review summarizes the available preclinical
and clinical literature focusing on graft characteristics,
defined as the cell types found in the graft (eg, CD341
or CD31; see Table 1 for hematopoietic cell marker
definitions) [27] and the gene expression profiles of
those cells. Specifically, we discuss how graft charac-
teristics can affect bone marrow homing, engraftment,
immune reconstitution, and outcomes after autolo-
gous or allogeneic HSCT.MECHANISMS OF HSC MOBILIZATION
HSCs exist at a very low (0.04%) frequency in
steady-state peripheral blood [28,29]. Most HSCs
remain tethered to the bone marrow through
adhesion molecule/receptor interactions with bone
marrow stromal cells, osteoblasts, and osteoclasts
[30]. Several protein-protein interactions help anchor
HSCs within the bone marrow, including the
chemokine receptor CXC motif receptor 4 (CXCR4)
and its cognate ligand stromal cell-derived factor-1
(SDF-1, or CXCL12), CD44/hyaluronic acid, c-kit/
kit ligand, VLA-4/vascular cell adhesion molecule-1
(VCAM-1) or fibronectin, and CD62/CD62L or
L-selectin [31-34].
Current mobilization regimens increase HSCs in
the peripheral blood above steady-state levels by dis-
rupting the normal bone marrow microenvironment
through several mechanisms (Figure 1). After chemo-
therapy administration, CD341 cells in peripheral
blood increase as the patient’s white blood cell count
starts to recover [35]. Although the exact mechanism
of this remains poorly characterized, neutrophil prote-
ases capable of adhesion molecule cleavage (eg, neu-
trophil elastase [NE], cathepsin G [CG]) accumulate
in the bone marrow and likely contribute to HSC
release from the bone marrow into the peripheral
blood [36]. G-CSF is thought to catalyze HSC
mobilization by down-regulating mRNA and protein
levels of the chemokine SDF-1 and by promotingaccumulation of matrix metalloproteinase-9 (MMP-
9), NE, and CG, which can cleave kit ligand and
SDF-1 in addition to VCAM-1 [36-40]. In contrast,
plerixafor is a direct CXCR4 antagonist that
reversibly inhibits the CXCR4–SDF-1 interaction,
releasing HSCs from the bone marrow into the
peripheral blood [41-46].IMPACTOF NOVEL MOBILIZATION
REGIMENS ON POOR MOBILIZERS
Numerous factors, including age, previous rounds
of chemotherapy, previous radiation therapy, exposure
to lenalidomide or alkylating agents, and bone marrow
involvement, have been identified as risk factors for
poor mobilization in patients with lymphoma and
MM [15,47-60]. Plerixafor in combination with G-
CSF has demonstrated the ability to overcome many
poor prognostic factors, including age [61], previous
chemotherapy [62], previous treatment with lenalido-
mide or fludarabine [63,64], failed first mobilization
attempt [65,66], and low platelet counts [61-67].
The scope of this review includes an evaluation of
whether HSCs mobilized by novel regimens in
predicted poor and failed mobilizers are of the same
quality as those collected from patients without such
risk factors. Cell cycle status, activation, and ex vivo
expansion kinetics have been shown to differ in G-
CSF–mobilized CD341 cells collected from ‘‘good’’
and ‘‘poor’’ mobilizers [68]; however, the clinical rele-
vance of these observations remains to be elucidated.
Recent clinical data have emerged regarding patients
with non-Hodgkin lymphoma (NHL)who failed a first
mobilization attempt and underwent successful remo-
bilization using plerixafor in combination with G-CSF
[66]. Median times to neutrophil and platelet engraft-
ment were similar in remobilized patients and those
who successfully mobilized on the first attempt; fur-
thermore, all patients maintained durable grafts at
the 12-month follow-up [66]. These data suggest
that the cells mobilized by plerixafor in patients who
failed previous mobilization are of at least the same
quality as those collected from patients during the first
mobilization attempt.TUMOR CELL MOBILIZATION
Tumor cells can be detected in the peripheral
blood of patients with MM and NHL before and
after mobilization [69-72]. The potential impact of
tumor cell reinfusion on patient outcomes following
aHSCT remains controversial, however. Small
studies have reported improved survival outcomes in
patients receiving grafts with a lower tumor burden
[73-76]. However, in randomized phase 3 trials,
CD341 cell selection resulted in a 2- to 3-log
Table 1. Hematopoietic Cell Markers
CD Antigen Cell Type Functions
CD3 Thymocytes and T cells Associated with the TCR and required for cell
surface expression of and signal transduction
by the TCR
CD4 Thymocyte subsets and T cells Coreceptor for MHC class II molecules and
receptor for HIV-1 and HIV-2 gp120; binds
Lck on cytoplasmic face of membrane
CD8 Thymocyte subsets and cytotoxic T cells Co-receptor for MHC class I molecules; binds
Lck on cytoplasmic face of membrane
CD11a (LFA-1) Lymphocytes, granulocytes, monocytes, and
macrophages
aL subunit of integrin LFA-1 (associated with
CD18); binds to CD54 (ICAM-1), CD102
(ICAM-2), and CD50 (ICAM-3)
CD25 Activated T cells, B cells, and monocytes IL-2 receptor a chain
CD31 (PECAM-1) Monocytes, platelets, granulocytes, T cell
subsets, and endothelial cells
Adhesion molecule; mediates both leukocyte-
endothelial and endothelial-endothelial
interactions
CD33 Myeloid progenitor cells and monocytes Binds sialoconjugates
CD34 Hematopoietic precursors and capillary
endothelium
Ligand for CD62L
CD38 Early B and T cells, activated T cells, germinal
center B cells, and plasma cells
NAD glycohydrolase; augments B cell
proliferation
CD45RA B cells, T cell subsets (naı¨ve T cells), and
monocytes
Tyrosine phosphatase; augments signaling
through antigen receptor of B and T cells
CD48 Leukocytes Putative ligand for CD244
CD49d (VLA-4) Broad distribution, includes B cells, thymocytes,
monocytes, granulocytes, and dendritic cells
a4 integrin; associates with CD29 and binds
fibronectin, MAdCAM-1, and VCAM-1
CD49e (VLA-5) Broad distribution, includes memory T cells,
monocytes, and platelets
a5 integrin; associates with CD29 and binds
fibronectin; invasion
CD54 (ICAM-1) Hematopoietic and nonhematopoietic cells Binds CD11a/CD18 integrin (LFA-1) and
CD11b/CD18 integrin (Mac-1) receptor
CD58 (LFA-3) Hematopoietic and nonhematopoietic cells Adhesion molecule; binds CD2
CD62L (L-selectin) B cells, T cells, monocytes, and NK cells Leukocyte adhesion molecule; binds CD34 and
GlyCAM and mediates rolling interactions
with endothelium
CD90 (Thy-1) CD34+ prothymocytes Unknown
CD106 (VCAM-1) Endothelial cells Adhesion molecule, ligand for VLA-4
CD110 Platelets MPL (TPO) receptor
CD133 Stem/progenitor cells Unknown
CD150 Thymocytes and activated lymphocytes Unknown
CD184 (CXCR4) Preferentially expressed in the more immature
CD34+ hematopoietic stem cells
Binds to SDF-1; acts as a cofactor for fusion and
entry of T cell line
GlyCAM indicates glycosylation-dependent cell adhesion molecule; HIV, human immunodeficiency virus; ICAM, intercellular adhesion molecule; IL,
interleukin; LFA, leukocyte function antigen; MAdCAM, mucosal addressin cell adhesion molecule; MHC, major histocompatibility complex; MPL,
myeloproliferative leukemia virus oncogene; NAD, nicotinamide adenine dinucleotide; NK, natural killer; PECAM, platelet endothelial cell adhesion
molecule; TCR, T cell antigen receptor; TPO, thrombopoietin.
Adapted with permission [27].
Biol Blood Marrow Transplant 16:1629-1648, 2010 1631Plerixafor-mobilized Graft Characteristicsreduction in graft tumor cell contamination but did
not impact engraftment, median overall survival
(OS), disease-free survival, or relapse rate [77,78]. In
addition, a recent study demonstrated no difference
in progression-free survival (PFS) or OS in MM and
NHL patients receiving autografts with or without
detectable tumor cells [79].
Autograft tumor contamination has been shown to
vary by HSC source and apheresis day. Several studies
have shown that peripheral blood HSC collections are
less likely to contain tumor cells compared with bone
marrow collections [80-85]. In particular, 2 studies
that compared premobilization bone marrow
harvests with mobilized peripheral blood autografts
from the same patients found that bone marrow
harvests were contaminated at higher frequencies and
with greater numbers of tumor cells [80,85]. These
findings are not universal, however; other studieshave found that peripheral blood collections were at
least as likely to be contaminated by tumor cells as
bone marrow harvests [86,87]. Interestingly, tumor
cell contamination also might vary by apheresis day.
Whereas some groups have observed no increase in
tumor cell load, others found that grafts collected on
apheresis day 5 or 6 were more likely to be
contaminated by tumor cells [80,88-90]. Whether
reducing the number of days required to collect
HSCs would reduce tumor burden remains an open
question.
Whether or not graft tumor contamination varies
by mobilization regimen is an important consider-
ation. Autografts collected after either chemomobili-
zation or cytokine-alone mobilization have been
shown to contain tumor cells [91-93]. Several groups
have investigated the impact of the novel agent
plerixafor on tumor cell contamination. In clinical
Figure 1. Mechanisms of stem cell mobilization. G-CSF mobilizes CD341 cells via down-regulation of SDF-1 expression and induction of CD26/dipep-
tidyl peptidase IV (DPPIV) cleavage of cell surface SDF-1. In addition, G-CSF stimulates polymorphonuclear leukocyte cell release of the proteases NE,
CG, andMMP-9, which cleave VCAM-1, c-kit, and SDF-1, releasing stem cells from the bonemarrow into the peripheral blood. Plerixafor mobilizes stem
cells through direct antagonism of CXCR4, which inhibits the interaction of SDF-1 with CXCR4. (Adapted from Future Oncol. 2005;1:375-383, with
permission of Future Medicine, Ltd.)
1632 Biol Blood Marrow Transplant 16:1629-1648, 2010S. Fruehauf and G. Tricotstudies of patients with NHL and MM, increased
mobilization of tumor cells over that detected after
administration of G-CSF alone was not observed
following the addition of plerixafor [94-96].GRAFT CONTENT STUDIES IN PRECLINICAL
MODELS, AUTOLOGOUS TRANSPLANT
RECIPIENTS, AND ALLOGENEIC
TRANSPLANT DONORS
Graft Cell Types
Cell types in grafts collected from unmobilized or
G-CSF–mobilized bone marrow—typically collected
by surgical bone marrow harvest—or in mobilized pe-
ripheral blood collected by apheresis differ in terms of
primitive hematopoietic progenitors, total T cells,
dendritic cells (DCs), and regulatory T cells (Tregs).
In turn, the abundance of these cell types can affect
transplantation outcomes. Primitive progenitors are
present in high numbers/frequency in mobilized pe-
ripheral blood, are highly clonogenic, and have been
shown to improve early neutrophil and platelet
engraftment and long-term progenitor cell recovery
after aHSCT [97-101].
DCs are antigen-presenting cells that prime naı¨ve
T cells to new antigens. There are 2 major types: my-
eloid DCs (DC1) and lymphoid DCs (DC2) [102].
Myeloid DCs typically drive T cell differentiation to-
ward T-helper1 (Th1) cells that promote cytotoxic Tlymphocytes, which can contribute to GVHD and
also to a graft-versus-leukemia effect in allogeneic
transplant recipients [103-105]. Lymphoid DCs can
drive T cell differentiation toward T-helper2 (Th2)
cells, which stimulate primarily B cells [103,104].
Infusion of higher total lymphocyte doses has been
shown to benefit immune reconstitution, OS, and
PFS in autologous transplant recipients [106-108]. In
allogeneic transplant recipients, increased graft
Tregs and DC2s can help reduce GVHD [109-111].
Studies of graft content in preclinical models,
autologous transplant recipients, and allogeneic
transplant donors have identified differences in graft
content depending on the source and/or mobilization
regimen.
Graft content in preclinical models
Preclinical work in mice has shown that mobiliza-
tion with G-CSF or chemotherapy 1 G-CSF
resulted in the collection of cells with superior clono-
genicity (based on the presence of colony-forming
units [CFU]-culture and CFU-spleen) compared
with unmobilized peripheral blood capable of
short-and long-term engraftment and repopulation
[112-115]. One study found that the clonogenicity
of chemomobilized cells was greater than that of
G-CSF–mobilized cells [113]. Regarding immune
cell phenotypes, mobilization with G-CSF has been
shown to induce polarization toward DC2s in mice
[116].
Biol Blood Marrow Transplant 16:1629-1648, 2010 1633Plerixafor-mobilized Graft CharacteristicsPreclinical studies in mice have compared the mo-
bilization of primitive hematopoietic precursors by
several mobilization agents [46,117,118]. Three-fold
more Sca-11 c-kit1 lineage (SKL) cells, which
contain long-term multipotent progenitor cells, were
collected per milliliter of blood in mice mobilized
by plerixafor 1 G-CSF than in mice mobilized by
G-CSF alone [46,119,120]. Recent studies in mice
also have examined the use of the CXCR2 agonist
GROb (CXCL2), either alone or in conjunction
with G-CSF or plerixafor, for the mobilization of
primitive hematopoietic precursors [117,118]. The
combination of plerixafor and GROb mobilized
approximately twice as many CD1501CD482 SKL
cells (which are involved in T cell development [121-
123]) and markers of long-term repopulating cells
compared with G-CSF, plerixafor, or GROb alone
[118]. In addition, SKL cells mobilized by plerixafor 1
GROb expressed higher levels of the adhesion receptors
CD11a (leukocyte function-associated antigen [LFA]-
1), CD49e (VLA-5), and CD49d compared with those
mobilized by plerixafor or GROb alone, which may
contribute to improved bone marrow homing [118].
Annexin V staining of mobilized cells showed that G-
CSF (6.4% 6 1.5%), plerixafor (10.4% 6 2.6%), and
GROb (4.5% 6 1.2%) alone each mobilized a greater
percentage of apoptotic cells compared with the com-
bination of plerixafor 1 GROb (2.9% 6 0.4%) [118].
Although not compared directly with chemomobiliza-
tion in these studies, novel combinations of mobi-
lization agents have the potential to mobilize more
primitive HSCs, which have a greater capacity for
repopulation.
Graft content in autologous transplant recipients
Current regimens mobilize grafts with varying clo-
nogenicity. Although the use of G-CSF has been
shown to stimulate the release of cells with high clono-
genic potential, several studies have suggested that
chemomobilized grafts may have greater clonogenic
potential, as evidenced by the collection of 2- to 4-
fold more burst-forming unit erythrocytes and 2- to
6-fold more CFU–granulocyte-macrophage (CFU-
GM) per nucleated cell compared with those collected
after cytokine-only mobilization (see Table 2 for
a summary of autologous graft content) [97,124-
137]. Long-term culture-initiating cells (LTC-ICs)
also were found at 12-fold higher levels in chemomo-
bilized grafts compared with grafts mobilized by
G-CSF alone [124]. After 4 days of G-CSF administra-
tion, plerixafor administration was shown to increase
the frequency of LTC-ICs by a further 1.6-fold [128].
Mobilization with G-CSF, chemotherapy 1
G-CSF, or plerixafor1G-CSF has been shown tomo-
bilize primitive hematopoietic precursors, including
CD341CD332, CD341CD382, CD341CD1331,
CD341Thy11, and CD341HLADR2 cells [125,128,138-140]. The presence of primitive precursors, such
as CD341CD332 cells, has been shown to be
predictive of platelet engraftment after aHSCT
[100,141]. The effects of cyclophosphamide on
CD341CD332 cell collection have been mixed. One
study reported a higher percentage of these cells in
patients mobilized by cyclophosphamide 1 G-CSF
than in patients mobilized by G-CSF alone, whereas
CD341CD382, CD341Thy11, and CD341HLADR2
subsets remained unchanged [125]; however, a second
study found that mobilization with cyclophosphamide
1 G-CSF decreased the number of immature CD341
cells [139]. In a third study, the proportion of prim-
itive CD341CD382 progenitors (as a percentage of
total CD341 cells) was higher in patients mobilized
by G-CSF than in patients mobilized by chemother-
apy 1 G-CSF; however, this difference was offset by
a higher total number of cells collected in the
chemotherapy 1 G-CSF group, which resulted in
higher CD341CD382 cell counts in the apheresis
product [97]. Plerixafor administration resulted in
a nearly 3-fold greater proportion and an 8-fold
greater number of primitive CD341CD382 precur-
sors in the peripheral blood compared with 4 days
of G-CSF mobilization [128]. Although not com-
pared directly, chemotherapy, cytokines, and plerixa-
for each preferentially mobilize different primitive
progenitor subsets.
Specific immunomodulating graft cell subsets, in-
cludingDCs, are altered aftermobilization with differ-
ent regimens. In one study, G-CSF administration
increased DC1 by 2.6-fold and DC2 by 5.9-fold in
the peripheral blood [129], whereas in a second study,
total DCs increased 2-fold after G-CSF mobilization
[130]. The effects of chemomobilization on graft DC
content and polarization have been mixed [130-133].
Regarding polarization, one group showed that
chemomobilization polarized DCs toward DC2s,
with the DC1:DC2 ratio decreasing by 10-fold in
apheresis collections [133]. Similarly, another study
demonstrated that mobilization with chemotherapy
1 G-CSF yielded a higher proportion of DC2s in
the graft and a lower DC1:DC2 ratio compared with
chemotherapy 1 G-CSF 1 GM-CSF [134]. In con-
trast, Gazitt et al. [131] reported no DC polarization
after chemomobilization with cyclophosphamide in
combination with G-CSF, GM-CSF, or G-CSF 1
GM-CSF. However, a greater number of total DCs
were found to be mobilized by cyclophosphamide 1
GM-CSF than by cyclophosphamide 1 G-CSF; cy-
clophosphamide 1 G-CSF 1 GM-CSF mobilized an
intermediate number of DCs [132]. Plerixafor admin-
istration after 4 days of G-CSF resulted in a more
than 2-fold further increase in both DC1s and DC2s,
with no additional DC polarization [135]. Because
increased pretransplantation and posttransplantation
total DC levels are known to correlate with longer
Table 2. Cell Types Mobilized by G-CSF, Chemotherapy, or Plerixafor in Autologous Transplant Recipients
Cell Type G-CSF Mobilization Chemomobilization Plerixafor Mobilization
Clonogenic Greater numbers of clonogenic
cells and LTC-IC than G-CSF
mobilization [124-127]
Higher frequency of LTC-IC
compared with G-CSF
mobilization [128]
Primitive hematopoietic
precursors
Higher proportion of
CD34+CD382 cells
compared with
chemomobilization [97]
Higher proportion of
CD34+CD332 cells
compared with G-CSF
mobilization [125]
Higher absolute number of
CD34+CD38- cells compared
with G-CSF mobilization [97]
Greater proportion and
number of CD34+CD382
cells compared with G-CSF
mobilization [128]
Dendritic cell Total cells increased compared
with bone marrow [129,130]
DC2 preferentially mobilized
[129,130]
Polarization results are mixed
[130-134]
No further polarization
observed when administered
following 4 days of G-CSF
[135]
Regulatory T cells Proportion of CD25+ cells
increased [136]
CD3+ T cells Increased compared with
G-CSF mobilization [137]
CD4+ T cells Increased compared with
G-CSF mobilization [137]
CD8+ T cells Increased compared with
G-CSF mobilization [137]
Natural killer cells Increased compared with
G-CSF mobilization [137]
1634 Biol Blood Marrow Transplant 16:1629-1648, 2010S. Fruehauf and G. TricotOS, examining whether elevated graft DC levels di-
rectly correlate with improved aHSCT outcomes
[142] is of interest.
Other types of cells, including immunosuppressant
Tregs, cytotoxic T cells, and natural killer (NK) cells,
also are collected from patients. After G-CSF mobili-
zation, Tregs were found to be nearly 3-fold higher in
the peripheral blood of patients with NHL and MM
[129]. Cyclophosphamide mobilization has been
shown to decrease T cell counts by 3-fold compared
with baseline. By the time of collection, most chemo-
mobilized patients will recover only one-third of their
baseline T cell levels. Although the relative ratios of
most T cells (ie, CD41 central memory, effector mem-
ory, late effector, and CD81 cells) did not change from
pre-cyclophosphamide therapy measurements, the
proportion of CD251 cells (including Tregs) in-
creased by 2- to 3-fold [136]. Cyclophosphamide has
been shown to be toxic to Tregs, and their presence
in chemomobilized autografts might be attributed to
G-CSF administration [143,144]. A recent study
demonstrated a significantly higher Treg content in
autologous grafts mobilized by plerixafor 1 G-CSF
compared with chemomobilized grafts (median,
11.3% vs 7.5%; P 5 .04) [145]. Consistent with their
function as immunomodulators, Tregs have been
shown to inhibit the cytotoxicity of autologous
CD81T cells in vitro and thusmight suppress antican-
cer immune responses in patients [146-151]. Whether
infused Treg levels correlate with immunosuppression
and anticancer immune activity in patients remains to
be elucidated. Regarding immune cell graft content,
CD31, CD41, and CD81 T cells and NK cells
increased 4-fold, 5-fold, 2.5-fold, and 3-fold more,respectively, in collections from patients mobilized
by plerixafor 1 G-CSF than in patients mobilized by
G-CSF alone [137]. Interestingly, immune cell subsets
were shown to vary by mobilization day (1 vs 2) and
disease (NHL vs MM); specifically, more CD31,
CD41, and CD81 cells were collected on apheresis
day 1 compared with day 2. Comparing disease state,
fewer CD41, CD191, and CD561 cells were collected
in NHL patients compared with myeloma patients
[152]. Infusion of higher lymphocyte and NK cell
doses has been shown to improve immune
reconstitution and to be correlated with better OS
and PFS [106-108].
Allogeneic graft content
The cell content of allogeneic grafts isolated from
healthy donor bone marrow, mobilized peripheral
blood, or both have been analyzed, with a focus on
primitive progenitors, clonogenic potential, and
total T cell, Treg, and DC populations (see Table 3
for a summary of allogeneic graft contents)
[104,133,138,139,145,153-159]. Although grafts
mobilized by G-CSF contain fewer primitive
hematopoietic precursors, they have been shown to be
as clonogenic as bone marrow, based on LTC-IC fre-
quency [139,153]. The proportion of myelomonocytic-
committed cells was found to be significantly higher in
peripheral blood than in bonemarrow, but the propor-
tion of erythroid progenitors in peripheral blood was
not significantly different from that in bone marrow
[139]. The utility of plerixafor as a mobilization agent
in allogeneic donors also has been explored. In terms
of clonogenic potential, plerixafor has been shown to
mobilize CFU-GM and burst-forming unit
Table 3. Cell Types Mobilized by G-CSF or Plerixafor in Allogeneic Transplant Donors
Cell Type G-CSF Mobilization Plerixafor Mobilization
Clonogenic Similar composition to bone marrow [139]
Primitive hematopoietic precursors Fewer primitive precursors than bone marrow [153] Similar levels compared with G-CSF mobilization [138]
Higher levels of primitive CD34dim population [154]
Dendritic DC2 preferentially mobilized [104,133]
Regulatory T cells Little change in levels compared with bone marrow
[145,155]
CD3+ T cells Increased compared with bone marrow [156,157] Increased compared with G-CSF mobilization [158,159]
CD4+ T cells Increased compared with bone marrow [156,157] Increased compared with G-CSF mobilization [159]
CD8+ T cells Increased compared with bone marrow [156,157]
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portion of primitive progenitors present in apheresis
products from individuals who received plerixafor
and then G-CSF, with a 10-day washout period
between treatments, revealed no significant differences
in the CD341 subtypes CD341CD1332, CD341
CD1331, CD341CD382, and CD341CD381 [138].
Interestingly, a new population of CD341 cells was
recently identified after plerixafor treatment. Flow
cytometric analysis of CD341 cell subsets mobilized
by either plerixafor or G-CSF in healthy donors
identified a CD34dimCD45RA1 cell population that
is unique to plerixafor-mobilized donors (60%;
6 of 10 donors analyzed) [154]. Up to 20% of
CD341 cells in plerixafor-mobilized grafts were
CD34dimCD45RA1 cells, compared with \2% of
G-CSF–mobilized CD341 cells [154]. Extensive
fluorescence-activated cell sorting and functional anal-
yses have demonstrated that these cells are plasmacy-
toid progenitors of DC2s. These CD34dimCD45RA1
cells express high levels of the proliferation marker
Ki-67 [160]. The extent to which these highly prolifer-
ative cells survive the freeze-thaw process that is
routinely applied in the autologous setting is currently
unclear and requires further study. In summary, plerix-
afor may mobilize more primitive and different
additional precursors than other agents.
DCs are important immunomodulatory cells, and
an increased DC2 dose has been correlated with a de-
creased incidence of GVHD in allogeneic transplant
recipients [111]. Arpinati et al. [104] reported that
G-CSF treatment induced DC polarization toward
DC2s in healthy donors, and approximately 5-fold
more DC2s were found in peripheral blood than in
bone marrow. Similarly, another study showed that al-
though G-CSF mobilization did not alter the propor-
tion of total DCs in the collected graft, the DC1:DC2
ratio decreased by 8-fold, suggesting that DC2s are
mobilized preferentially [133].
T cell content can have a profound effect on allo-
geneic transplantation outcomes. For example, high
CD31 T cell doses have been associated with an
increased incidence of acute GVHD (aGVHD)
[161,162]. G-CSF mobilization results in at least 4-
fold more T cells in peripheral blood than in
unmobilized bone marrow [156,157], whereas levelsof effector memory and naı¨ve T cells decrease during
G-CSFmobilization [155]. Grafts mobilized by plerix-
afor alone or in combination with G-CSF have an even
higher T cell content than those mobilized by G-CSF
[158]. Devine et al. [159] reported greater numbers of
CD31 and CD41 T cells in grafts collected after mo-
bilization with single-agent plerixafor than in grafts
collected after mobilization with G-CSF [159].
Although plerixafor-mobilized grafts have a higher
T cell content than bone marrow, allogeneic trans-
plantation of these cells in a small cohort of patients
does not appear to increase the aGVHD rate to above
that in than historical controls. Although these results
require further validation in a larger trial, they suggest
that either plerixafor-mobilized T cells or other graft
characteristics may contribute to greater host toler-
ance [156,159].
Tregs have demonstrated the ability to combat
GVHD, and their presence in allogeneic grafts has
been shown to correlate with reduced GVHD and
improved OS [109]. Treg levels have been shown to
vary little in allogeneic donors regardless of the mobi-
lization regimen used; for instance, studies comparing
unmobilized bone marrow or peripheral blood and
G-CSF–mobilized peripheral blood have found no
difference in Treg levels [145]. Compared with MM
or NHL patients, healthy donors mobilized fewer
Tregs [145]. However, 3 weeks after the completion of
G-CSF treatment, Treg levels were found to be twice
as high in mobilized peripheral blood than in
unmobilized peripheral blood [155]. In contrast,
CD31CD42CD82 Tregs were preferentially mobi-
lized by G-CSF and found in higher numbers in mobi-
lized peripheral blood than in unmobilized bone
marrow [163]. The Treg content of plerixafor-
mobilized donors has not yet been evaluated. Although
Tregs have not been shown to be mobilized to a great
extent by G-CSF, given their ability to modulate
GVHD, their presence in the graft may be of great
importance to allogeneic HSCT.
Depending on the regimen used (G-CSF, plerixa-
for, or a combination), the first day of collection varies
with respect to donor mobilization initiation. For
example, individuals who received single-agent plerix-
afor in the studies by Liles et al. [158] and Devine et al.
[159] underwent apheresis on day 1 or day 5 of
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these studies, the plerixafor-treated donors, in whom
mobilization and collection occurred on the same
day, exhibited higher T cell levels in their grafts com-
pared with those mobilized byG-CSF alone [158,159].
The number of T cells collected when plerixafor was
combined with G-CSF was lower than the number
collected when plerixafor alone was used, but was
significantly higher than the number collected after
G-CSF alone [158]. The foregoing findings suggest
that different mobilization regimens and administra-
tion schedules might result in differential mobilization
kinetics of various cell subsets, which in turn could
affect the graft content.Cell Cycle Status
Although in vitro tests and transplantation studies
have found that the cell cycle has little functional effect
on hematopoietic engraftment, cell cycle status may be
important when considering ex vivo graft manipula-
tions. For example, when considering the use of a purg-
ing agent to eliminate cancer cells from autografts, an
understanding of the cell cycle of normal HSCs is crit-
ical. A cell cycle–dependent purging technique may
better spare normal HSCs collected from the periph-
eral blood while targeting cancer cells undergoing
division. Some cancerous cells are also noncycling,
however. Differences in the cell cycle status of bone
marrow and mobilized peripheral blood have been
demonstrated.
Mobilized peripheral bloodHSCs have a markedly
different cell cycle profile than bone marrow HSCs.
Data from preclinical models and from individuals
undergoing mobilization for an autologous or alloge-
neic transplantation suggest that G-CSF mobilization
results in a lower proportion of cells in S/G2/M in mo-
bilized peripheral blood than in unmobilized bone
marrow [140,164,165]. This cell cycle profile
correlates with a gene expression profile showing
increased expression of cell cycle inhibitory genes in
G-CSF–mobilized peripheral blood [166]. The effect
of chemomobilization on cell cycle status has been
investigated in preclinical models and autologousTable 4. Gene Expression Changes Following Mobilization in Precl
Gene/Gene Category Mobilization Regimen
CXCR4 Plerixafor
VLA-4 Plerixafor
VLA-5 Plerixafor
CD62L (L-selectin) G-CSF
Adhesion molecules Plerixafor or G-CSF
T cell-related Plerixafor
B cell-related Plerixafor
Mast cell-related Plerixafor
Neutrophil-related G-CSF
Macrophage-related G-CSFtransplant recipients and found to be similar to that
seen with G-CSF [115,140,164]. Finally, although
plerixafor-mobilized peripheral blood HSCs appear
to have a cell cycle profile more closely related to
that of bone marrow HSCs than to that of HSCs mo-
bilized using other regimens, most of the mobilized
CD341 cells are not in the S/G2/M phase.Gene Expression Analysis
Given that mobilization regimens vary with
respect to mechanism of action, the finding that gene
expression profiles differ in the same cell types mobi-
lized by different methods is not unexpected. Altered
gene expression can lead to phenotypic changes that
dictate HSC viability, homing capability, and engraft-
ment potential.
Preclinical gene expression data
Global gene (17,500 cDNA probes) microarray
analysis of CD341 cells isolated from macaques that
received G-CSF, plerixafor, G-CSF 1 plerixafor, or
plerixafor alone yielded 3 distinct clusters [167]. Genes
expressedbyTcells, B cells, andmast cellswereenriched
in plerixafor-mobilized cells, whereas genes expressed
by neutrophils and macrophages were enriched in
G-CSF–mobilized cells (Table 4) [46,167-169]. Genes
expressed by B cells were enriched in plerixafor 1
G-CSF–mobilized cells to a greater degree than in
cells mobilized by either agent alone [167]. These data
suggest that the phenotypes of cells mobilized by
plerixafor 1 G-CSF may vary considerably from those
mobilized by either agent alone.
Individual genes postulated to be involved in bone
marrow homing and engraftment have been shown to
vary with different mobilization regimens. One study
in macaques found that a significantly higher propor-
tion of plerixafor-mobilized CD341 cells expressed
CXCR4 both on the cell surface and intracellularly
compared with G-CSF (53% 6 23% vs 11% 6 9%;
P 5 .02) [168]. Similarly, gene expression of CXCR4
also was found to be significantly up-regulated in
plerixafor-mobilized cells [167]. The adhesion mole-
cule VLA-4 also was expressed at a significantly higherinical Models
Expression Change
Increased compared with G-CSF mobilization [167,168]
Increased compared with G-CSF mobilization [168]
Increased compared with G-CSF mobilization [46]
Increased compared with plerixafor mobilization [46]
Lower compared with unmobilized bone marrow [169]
Increased compared with G-CSF mobilization [167]
Increased compared with G-CSF mobilization [167]
Increased compared with G-CSF mobilization [167]
Increased compared with plerixafor mobilization [167]
Increased compared with plerixafor mobilization [167]
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in G-CSF–mobilized CD341 cells (71% 6 13% vs
41% 6 23%; P 5 .03). These cell surface proteins
may have contributed to the superior in vitro migra-
tion toward SDF-1 and the enhanced repopulating
ability of plerixafor-mobilized cells relative to cells
mobilized by G-CSF alone [168]. Cell surface expres-
sion of either protein did not differ significantly be-
tween plerixafor-mobilized peripheral blood and
bone marrow [168]. CD341 cells mobilized by plerix-
afor 1 G-CSF expressed significantly higher levels of
the adhesion protein VLA-5, whereas G-CSF–mobi-
lized CD341 cells expressed significantly higher
CD62L levels and included a greater proportion of
cells expressing CD62L [46]. In mice, cell surface
expression of several adhesion molecules, but not of
CXCR4, was higher in bone marrow cells than in pler-
ixafor- or G-CSF–mobilized cells, suggesting that
hypoadhesion may be a prerequisite for bone marrow
egress [169].
Gene expression studies in autologous and
allogeneic grafts
Because of its central role inHSCmobilization and
engraftment, CXCR4 expression has been monitored
in several studies, and its expression has been found
to differ depending on mobilization regimen (Table
5) [128,166,170-173]. CD341 cells isolated from the
peripheral blood of NHL patients mobilized by
cyclophosphamide 1 G-CSF, GM-CSF, or G-CSF
followed by GM-CSF all exhibited lower CXCR4
expression compared with premobilized peripheral
blood CD341 cells [170]. Mobilization with G-CSF
resulted in a greater CXCR4 expression in allogeneic
grafts than in bone marrow [166,174]. Cell surface
CXCR4 expression was found to decrease after
plerixafor administration; however, expression
rebounded to pre-plerixafor levels in the apheresis
product [171]. Two other studies reported higher
CXCR4 expression in peripheral blood CD341 cells
after plerixafor administration in combination with
G-CSF compared with G-CSF alone [128,172].
CXCR4 expression may affect bone marrow homing
[40] and, unlike cytokine or plerixafor mobilization,
may be negatively affected by cyclophosphamide. In-
creased adhesion molecule expression may benefit
bone marrow homing but be detrimental to HSC mo-
bilization. Interestingly, decreased CXCR4 expression
has been shown to correlate with improved HSC
mobilization [174]. Conversely, lower CD341 cell
harvests from bone marrow have been shown to corre-
late with decreased CXCR4 expression [174].
The expression of several gene types that might
contribute to transplant cell survival and engraftment
is different in bone marrow and mobilized peripheral
blood. One study found that CD341 cell expression
of cell cycle progression and DNA synthesis geneswas greater for bone marrow compared with G-
CSF–mobilized peripheral blood, whereas expression
of cell cycle inhibition and apoptosis genes (including
caspases 3, 4, and 8) was greater in G-CSF–mobilized
peripheral blood [166]. The cell cycle gene expression
profile is more closely correlated with cycling of more
bone marrow HSCs than peripheral blood HSCs
[165]. Interestingly, long-term changes in gene expres-
sion have been documented in donors mobilized by
G-CSF, with 53 cell growth, proliferation, and com-
munication genes up-regulated and 69 of these genes
down-regulated up to 9 months after mobilization
[175]. Compared with G-CSF alone, CD341 cells mo-
bilized by plerixafor 1 G-CSF had higher expression
of antiapoptosis, cell cycle promotion, cell adhesion,
and cell motility genes and lower expression of proa-
poptotic genes [172]. Expression of the adhesion
molecules LFA-1, CD62L, CD44, VLA-4, or platelet
endothelial cell adhesion molecule did not differ
significantly before and after plerixafor administration
after 4 days of G-CSF mobilization [171]. Overall,
plerixafor-mobilized cells exhibit a gene expression
profile favorable to survival and bone marrow homing.
Many genes associated with Tregs were found to
be up-regulated in T cells isolated from G-CSF–
treated donor peripheral blood, but not in unmobi-
lized peripheral blood; many of these genes remained
up-regulated 3 weeks after G-CSF administration
[155]. In addition, the expression of genes associated
with Th1 cells decreased, whereas those associated
with Th2 cells increased, providing further evidence
of the Th2 polarization of G-CSF–mobilized donors
[155]. Importantly, genes associated with antigen pro-
cessing andGVHDwere down-regulated after G-CSF
administration [155]. These findings indicate that T
cells mobilized by G-CSF have a gene expression pro-
file suggesting greater tolerance toward host cells.
These data may partially explain why allogeneic trans-
plantation of G-CSF–mobilized grafts (with a higher
T cell content than bone marrow) was not associated
with significantly higher aGVHD rates [176]. How-
ever, over the long term, chronic GVHD (cGVHD)
rates are higher in patients who receive mobilized pe-
ripheral blood than in those who receive bone marrow,
suggesting the involvement of other factors [176].
RNA profiling can provide global assessments of
gene expression changes. The RNA profiles of healthy
donor CD341 cells isolated from bone marrow clus-
tered more closely with plerixafor-mobilized HSCs
than withG-CSF–mobilizedHSCs [154]. This finding
suggests that global gene expression is altered to
a lesser extent when cells are mobilized by plerixafor
than when they are mobilized by G-CSF, and thus
plerixafor-mobilized cells may be more akin to bone
marrow than G-CSF–mobilized cells [154]. Interest-
ingly, genes up-regulated by a combination of
G-CSF and plerixafor included many not up-
Table 5. Gene Expression Changes Following Mobilization in Autologous Transplant Recipients and Allogeneic Transplant Donors
Gene/Gene Category Mobilization Regimen Expression Change
CXCR4 Chemomobilization Decreased compared with premobilization levels [170]
CXCR4 G-CSF Increased compared with unmobilized bone marrow [171]
CXCR4 Plerixafor Unchanged compared with premobilization levels [171]
CXCR4 Plerixafor + G-CSF Increased compared with G-CSF mobilization [128,172]
Cell cycle progression G-CSF Decreased compared with bone marrow [166];
decreased compared with plerixafor + G-CSF mobilization [172]
DNA synthesis G-CSF Decreased compared with bone marrow [166]
Antiapoptosis Plerixafor + G-CSF Increased compared with G-CSF mobilization [172]
Cell adhesion Plerixafor + G-CSF Increased compared with G-CSF mobilization [172]
Cell motility Plerixafor + G-CSF Increased compared with G-CSF mobilization [172]
Proapoptosis G-CSF Increased compared with plerixafor + G-CSF mobilization [172]
Hematopoiesis-associated miRNAs G-CSF, plerixafor, or plerixafor + G-CSF Increased compared with unmobilized peripheral blood [173]
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consistent with the concept of synergy between the 2
agents and suggests that the manner in which
CD341 cells are mobilized by the combination of G-
CSF and plerixafor may not be simply a function of 2
exclusive mechanisms of action. In addition, micro-
RNA (miRNA) profiling has demonstrated greater ex-
pression of hematopoiesis-associated miRNAs in
mobilized HSCs (regardless of regimen) compared
with unmobilized peripheral blood, suggesting
a greater repopulation capacity for HSCs [173]. Inter-
estingly, mobilization with plerixafor alone or in con-
junction with G-CSF resulted in a distinct miRNA
profile compared with G-CSF–mobilized cells [173].CLINICAL IMPLICATIONS OF GRAFT
CONTENT
The ultimate goal of mobilization for aHSCT is to
obtain cells that result in durable engraftment and
rapid and sustained hematopoietic recovery, which in
turn affects long-term outcomes, such as OS and
PFS. Similarly, for allogeneic HSCT, it is important
to collect grafts that will allow durable engraftment
and rapid hematopoietic recovery, and carry a minimal
risk of aGVHD and cGVHD. These goals are affected
both by the cell types present in the graft and by the
intrinsic qualities of these cells.Effect of Graft Content in Preclinical Models
Bone marrow homing
Bone marrow homing is a complex cellular activity
dependent on the coordination of intracellular gene
expression and the response to extracellular stimuli.
Using mouse models, Bonig et al. [177] identified
increased cell motility as a contributing factor to
improved bone marrow homing [177]. In general, mo-
bilized CD341 cells (irrespective of the mobilization
regimen used) display greater homing potential than
unprimed bone marrow [169,177]. It appears that
homing is dependent not only on CXCR4, but alsoon adhesion molecules and intrinsic cell motility
capacity [117,118,168,177].
Bone marrow repopulation
Homing capability can estimate the ability of cells
to migrate toward the bone marrow, but whether cells
actually engraft and repopulate once in the marrow
space is of great importance. Much of the recent pub-
lished data focus on novel mobilization agents, such as
plerixafor and GROb, with comparisons with G-CSF
often made. Competitive repopulation assays in mice
demonstrated that cells mobilized by plerixafor 1
G-CSF were more successful at repopulation com-
pared with cells mobilized by either agent alone [46].
Importantly, cells mobilized by plerixafor or plerixafor
1 G-CSF demonstrated a high capability of self-
renewal; transplanted cells isolated from a first recipi-
ent repopulated a second, lethally irradiated mouse
[46]. The effects of cell cycle on repopulation remain
largely uncharacterized. Ex vivo cell cycle activation
of CD341 cells has resulted in more rapid short-
term granulocyte recovery, but has not been correlated
with short-term or long-term engraftment in a nonhu-
man primate model of aHSCT [178].
Plerixafor was found to mobilize long-term repopu-
lating rhesus macaque cells as determined by gene
marking and competitive repopulation assays [168].
Plerixafor-mobilized peripheral blood mononuclear
cells (PBMCs) and granulocytes were still detectable 24
months posttransplantation,whereasG-CSF–mobilized
cells were not [168]. Similarly, a study in a canine model
system showed that plerixafor-mobilized PBMCs
supported aHSCT and allogeneic HSCT for more
than 1 year [179]. In another study, plerixafor 1
GROb mobilized 3-fold more marrow repopulating
units comparedwithG-CSF,plerixafor, orGROb alone.
Furthermore, the engraftment capacity of cells mobi-
lized by plerixafor1GRObwas superior to that of cells
mobilized by any agent alone, as determined by chime-
rism analyses 6months after competitive transplantation
[118]. These preclinical studies suggest that novel agents
and combination regimens may mobilize cells with
improved repopulation capacity.
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Bone marrow homing
With respect to clinical outcomes, better spontane-
ous and SDF-1–induced CD341 cell migration has
been correlated with faster neutrophil engraftment af-
ter transplantation, independent of cell dose [180]. In-
dividual gene contributions to bone marrow homing
remain unclear, however. For example, when examined
in isolation, CXCR4 expression were not correlated
with either spontaneous or SDF-1–induced migration
in cells mobilized by chemotherapy 1 G-CSF [180].
Interestingly, transplantation of CD341L-selectin1
cells was significantly better correlated with rapid
platelet engraftment than absolute CD341 cell dose,
suggesting that adhesion molecule expression benefits
homing [181]. Thus, cell migration is a more complex
process than simply the receipt of SDF-1 signals and
adherence.General cellmotility, the result of awide va-
riety of genes, contributes strongly to migration.
Plerixafor-mobilized grafts exhibit increased expres-
sion of genes that may facilitate migration and engraft-
ment, including those involved in antiapoptosis, cell
cycle promotion, and cell motility [172]. Whether ele-
vated expression of these gene types correlates with
improved engraftment remains to be seen.
Engraftment
Hematopoietic engraftment can be divided into
short-term recovery (ie, neutrophils, platelets, and red
blood cells) and long-term engraftment (ie, primitive
progenitor cells). The dose of infused CD341 cells re-
mains themost important determining factor of neutro-
phil and platelet engraftment [182-184]. The presence
of other graft cell subtypes also has been shown to
affect hematologic recovery, however; for example,
CD341CD332 cell dose (.1.38  106 CD341 cells/
kg) was shown to better predict platelet recovery
than CD341 cell dose [100]. In addition, higher
CD341CD332 cell doses were correlated with rapid
neutrophil recovery [99,141]. An increased dose of
CD341CD1101 cells (CD110 is the thrombopoietin
receptor, which is essential for platelet production
[185,186]) has been shown to be highly predictive of
platelet transfusion independence within 21 days after
transplantation [187]. Threshold values of 5 105 total
CFUs and 2.5  104 CFU-megakaryocytes also have
been shown to predict rapid platelet recovery [188].
The use of colony-forming cells and colony-forming
cells–megakaryocytes has been suggested when infused
doses are close to of below 2  106 CD341 cells/kg to
predict platelet recovery [188]. Taken together, the
contributions of a wide variety of cell types can both
predict and influence timely engraftment.
Human CD81CD31TCR2 cells were recently
shown to facilitate hematopoietic engraftment ofsuboptimal cell doses in nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice
[189]. When CD341 cells were cocultured with
CD81CD31TCR2 cells in vitro, hematopoietic col-
ony formation was increased and shown to be a direct
effect of CD81CD31TCR2 cells. Interestingly, these
cells have been shown to be present at 2- to 5-fold
higher levels in G-CSF–mobilized peripheral blood
than in bone marrow, cord blood, and normal periph-
eral blood, and may help facilitate engraftment of
peripheral bloodHSCs, especially in patients receiving
lower CD341 cell doses [189].
Because primitive progenitor cells have excellent
repopulation and proliferation capabilities [190,191],
increasing their numbers in grafts might improve
long-term engraftment outcomes. In fact, LTC-IC
number—notCD341 cell dose orGM-CFUnumber—
in mobilized peripheral blood was correlated with 1-
year marrow progenitor cell recovery after aHSCT
[101]. Conversely, the number of LTC-ICs auto-
grafted from bone marrow or peripheral blood (mobi-
lized or steady-state) did not correlate with short-term
neutrophil, platelet, or red blood cell recovery
[192,193]. In a study released in 2009, nearly all
patients (91%) who underwent transplantation with
G-CSF 1 plerixafor–mobilized peripheral blood
progenitor cells reached the target of full and
sustained platelet reconstitution (.150/nL) within
30 days [128]. In a previous study of chemomobilized
patients, the threshold of 150 platelets/nL was reached
within 180 days in only 63% of aHSCT recipients
[194]. Similarly, 65% of patients who received 2-7 
106 CD341 cells/kg required 1-7 months to reach
the same platelet threshold [195]. These data support
the notion that G-CSF 1 plerixafor–mobilized grafts
contain more primitive hematopoietic cells with supe-
rior long-term engraftment potential [128].
Immune reconstitution
Immune reconstitution after aHSCT is vital to
stave off infection and promote early survival. The
use of CD341-selected grafts (lymphocyte-depleted)
has allowed evaluation of the importance of accessory
cells with respect to immune reconstitution and infec-
tion. Absolute lymphocyte count (ALC) recovery is an
established surrogate marker for immune reconstitu-
tion, and improved ALC recovery posttransplantation
has been shown to be predictive of superior OS and
PFS [106,196,197]. In turn, infusion of greater
numbers of lymphocytes has been correlated with
improved OS and PFS [106-108]. Of several cell
types examined, only increased NK cell dose was
correlated with faster ALC recovery [106]. Interest-
ingly, NK cell numbers were shown to be 3-fold higher
in collections fromNHL patients mobilized by plerix-
afor 1 G-CSF compared with those mobilized by
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1 G-CSF–mobilized cells exhibited higher ALC re-
covery 15 days posttransplantation [137]. In addition,
after a median follow-up of 20 months, 0 of 7 patients
in the plerixafor1G-CSF group and 15 of 29 patients
in the G-CSF-alone group (52%) relapsed [137]. This
group did not explore a direct causal relationship be-
tween better ALC recovery and relapse rate, however.
Transplantation of higher doses of lymphocytes
(including CD31, NK, andCD81 cells) was correlated
with faster neutrophil recovery, whereas increased
CD41 cell doses were associated with decreased infec-
tion rates [139].
The potential contributions of other graft cell
types to aHSCT outcomes should not be ignored.
For example, DC contents both before and after trans-
plantation have been correlated with better survival
outcomes; specifically, high DC1 and total DC levels
before transplantation and high DC1, DC2, and total
DC levels after transplantation have been associated
with improved OS [142]. Although the impacts of sev-
eral cell types on aHSCT have been elucidated, other
relevant types likely remain to be identified.
Effect of Graft Content on Allogeneic
Transplantation Outcomes
Bone marrow repopulation
Timely bone marrow repopulation and engraft-
ment are the early goals of aHSCT, and mouse models
have been useful in assessing the bone marrow repopu-
lation of human HSCs mobilized by different regi-
mens. A pairwise comparison of donors mobilized
with plerixafor and then G-CSF demonstrated signifi-
cantly greater bone marrow repopulation in mice who
received 2  107 plerixafor-mobilized mononuclear
cells than in mice who received the same dose of G-
CSF–mobilized cells (P \ .05) [138]. Furthermore,
NOD/SCID repopulating cells were present at a sig-
nificantly higher frequency in plerixafor-mobilized
cells than in G-CSF–mobilized cells [138]. Similarly,
donors mobilized.3-fold more NOD/SCID repopu-
lating cells when given plerixafor compared with G-
CSF. However, G-CSF 1 plerixafor mobilized more
NOD/SCID repopulating cells than either treatment
alone, suggesting synergy between these agents [46].
T cell content and GVHD
The contributions of immune cell types to alloge-
neic transplantation outcomes have been difficult to
study in isolation. Increased doses of allogeneic
CD31 cells have been associated with increased
aGVHD, as well as with decreased treatment-related
mortality, better leukemia-free survival, and improved
OS [161,162]. In addition, Waller et al. [198] reported
that high doses of CD4bright T cells were associated
with decreased event-free survival and cGVHD, butwith increased relapse. Activated (CD1521) T cells
and NK cells were found to be negative predictors of
cGVHD in a prospective trial of allogeneic transplan-
tation [199]. Furthermore, the ratio of CD4 to CD8
cells was negatively associated with disease-free sur-
vival and OS [200]. Thus, several studies have indi-
cated that increased T cell content might contribute
to GVHD; however, the characteristics of the T cells
collected also may affect patient outcomes.
Despite a higher T cell content, G-CSF–mobilized
grafts are not necessarily associated with higher
aGVHD rates [156,201-203]. Devine et al. [159]
showed in a small cohort that despite higher T cell
content, allogeneic transplantation of plerixafor-
mobilized grafts was not associated with greater
aGVHD or cGVHD rates than those seen in a histor-
ical G-CSF–mobilized control population. These
results require further validation in a larger trial,
however. These findings suggest that the characteris-
tics of graft T cells are important when discussing
transplantation outcomes. For example, CD62L1
naı¨ve T cells have been shown to be more alloreactive
and thus may contribute more to GVHD compared
with CD62L2 memory T cells [204,205]. These cell
populations did not different in terms of peripheral
blood cell content before and after plerixafor
administration [159].
The mobilizing agent used also may play a role in
GVHD protection: Morris et al. [206] reported lower
alloreactivity in donor T cells mobilized by pegylated
G-CSF than in those mobilized by standard G-CSF.
Gene expression also is likely to influence GVHD,
and the profile of G-CSF–mobilized T cells suggests
greater host tolerance [155]. Another possible explana-
tion for the low incidence of GVHD is that G-CSF–
and plerixafor-mobilized grafts may contain more
Tregs, potentially offsetting the higher CD31 cell
levels. Thus, absolute levels of different cell types
may not sufficiently explain transplantation outcomes.
Further study into the cellular characteristics of grafts
is warranted.
Several studies have shown that transplanting
high numbers of Tregs can prevent GVHD in mice
[207-210], and the impact of Tregs has been studied
in allogeneic transplant recipients as well. In a study
of 34 patients undergoing HLA-identical sibling
donor HSCT after standard-intensity conditioning,
those receiving higher Treg doses had a 45% lower
cumulative incidence of aGVHD compared with those
receiving lower Treg doses [109]. Multivariate analysis
identified low graft Treg dose as an independent
prognostic factor for aGVHD [109]. Importantly, no
difference in relapse rate was seen between these
2 groups, and those receiving higher Treg doses had
better OS [109]. Similarly, patients experiencing early
(within 30-45 days after transplantation) Treg recov-
ery had a lower incidence of aGVHD [110].
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lower in patients with GVHD [110]. Treg frequency
has been shown to vary by mobilization regimen in
autologous transplant recipients [145]; further, vigor-
ous study in the allogeneic setting is needed, however.
Effects of dendritic cells on GVHD
The effect of DCs is also an important consider-
ation when discussing GVHD. Myeloid DCs typically
drive differentiation toward Th1 cells, which promote
cytotoxic T cells (contributors to GVHD), whereas
DC2 can drive T cell differentiation toward Th2 cells,
which promote allergic responses [103,104]. Larger
DC2 numbers have been correlated with significantly
shorter event-free survival, lower rates of cGVHD,
and higher rates of relapse [111]. Because G-CSF
treatment induces polarization toward DC2, the
higher T cell content observed in G-CSF–mobilized
grafts compared with bone marrow may be tempered
by increased DC2 levels [104]. Gene expression analy-
sis of plerixafor-mobilized donor cells has revealed no
evidence of T cell polarization [211]. Thus, DC polar-
ization may help modulate the impact of GVHD in
peripheral blood–derived grafts.CONCLUSION
This review has summarized current preclinical,
autologous, and allogeneic data on the characteristics
of grafts mobilized by different regimens and the ef-
fects of cell subsets on homing, engraftment, and
transplantation outcomes. In patients undergoing
aHSCT, DC and Treg graft contents vary after mobi-
lization with different regimens. Mobilization by G-
CSF stimulates the release of DCs, with a polarization
toward DC2s, whereas chemomobilization results in
similar polarization but without an increase in total
DC content [129,139]. Currently, no evidence
suggests DC polarization after mobilization with
plerixafor. Total Tregs increase after G-CSF
mobilization, and the proportion of Tregs in the
graft increase after chemomobilization [129,136,145].
DC levels are elevated in allogeneic donors after
G-CSF mobilization, and, as in autologous patients,
are polarized toward DC2s [104,133]. Greater
numbers of T cells have been found in G-CSF– and
plerixafor-mobilized peripheral blood than in unmobi-
lized bone marrow, but this has not been correlated
with increased aGVHD rates [156-159,201].
CD34 remains the most widely used surrogate for
HSC mobilization and collection efficacy. In fact,
baseline peripheral blood CD341 cell counts mea-
sured before mobilization with single-agent G-CSF
or chemotherapy 1 G-CSF can be used to estimate
the efficiency of mobilization and may help identify
those at risk for failure of mobilization [212,213]. Inaddition, postmobilization peripheral blood CD341
cell counts have been shown to be highly predictive
of successful collection and can be used to identify
poor mobilizers before failure of collection [214].
Some groups use a postmobilization CD341 cell count
of\10 cells/mL and others use a count of\20 cells/mL
as the trigger for administering plerixafor in an
attempt to avoid mobilization failure [215,216]
Preliminary analysis showed that for collecting the
minimum CD341 cell harvest (2  106 CD341 cells/
kg), a blood CD341 cell count of $10/cells/mL on
day 4 is required, whereas an optimal harvest (5 
106 CD341 cells/kg) requires a count of $20 cells/
mL on day 4 [217]. According to this algorithm, if
blood CD341 values fall below the utilized threshold,
then plerixafor should be added.
Although CD341 remains the most widely used
cell type for predicting aHSCT engraftment out-
comes, other cell subtypes are important as well.
G-CSF 1 plerixafor mobilization has resulted in
the collection of higher proportions of primitive
CD341CD382 cells [128]. Henon et al. [218] sug-
gested an optimal threshold of 5 104 CD341CD38
cells/kg of body weight for rapid and sustained en-
graftment. Future studies should readdress the rele-
vance of cell type–specific thresholds for CD341 or
CD341CD382 cells, particularly in poor mobilizers.
In the allogeneic HSCT setting, total T cell con-
tent, the presence of DCs, and the frequency of Tregs
have been shown to modulate GVHD. Improved un-
derstanding of the underlying mechanisms related to
HSCT (eg, homing, engraftment, GVHD, immune
reconstitution) may have implications for treatment
practices and patient outcomes. Furthermore, grafts
can be manipulated more extensively ex vivo to elicit
the desired response in patients; for example, CD341
selection could be applied to donor grafts, with the in-
tent of using a higher CD341 cell dose to ensure
higher rates of chimerism.
Although great strides have been made in our un-
derstanding of the biology of HSCT, much remains
to be elucidated. The gene expression studies pre-
sented in this review offer a good starting point for
the analysis of the differences among cells mobilized
by different regimens. A next step is to begin to draw
more correlations among the molecular characteristics
of collected cells, mobilization efficacy, and transplan-
tation outcomes. Continued evaluation of the contri-
butions to patient outcomes of different mobilization
regimens and the cell types mobilized by these regi-
mens is needed.ACKNOWLEDGMENTS
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